Pharmaceutical

Bayer’s new CEO was dealt a duo of ‘clearing events.’ T...

Want to stay on top of the science and politics driving biotech today? Sign up t...

STAT+: Pharmalittle: Texas sues Pfizer over ADHD drugs;...

The Texas attorney general is suing Pfizer over allegedly selling ineffective AD...

STAT+: Flagship Pioneering launches Quotient, a new bio...

Flagship Pioneering, the venture capital firm behind Moderna, unveiled a new bio...

STAT+: Mixed study results for MorphoSys blood-cancer d...

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target...

STAT+: How the CEO of the largest medical device accele...

MedTech Innovator is creating a vibrant community of innovators, injecting a you...

Opinion: Filling 12-month prescriptions is one practica...

Getting a year’s worth of a maintenance medication in one visit makes life easie...

Invisible in the data: Broad ‘Asian American’ category ...

Blending together the highly diverse pool of Asian Americans in widely used metr...

STAT+: Delay of eye drop recall highlights FDA’s impote...

It took the FDA a while to coax companies to take certain eye drops off shelves....

STAT+: Pharmalittle: CRISPR pioneers reflect on future ...

The U.K. and the pharma industry reached a deal on a five-year plan outlining ho...

Merck cough drug doesn’t pass panel scrutiny

Want to stay on top of the science and politics driving biotech today? Sign up t...

STAT+: U.K., pharma industry strike deal for how the NH...

The U.K. and pharma industry have reached a deal on how the health system pays f...

STAT+: What Eli Lilly’s Zepbound reveals about the intr...

The story behind the Zepbound moniker offers insight into the marketing differen...

STAT+: How a major hospital shows just how inflated hos...

Hospitals’ list prices always come with massive discounts. Financial documents a...

STAT+: Hospitals put tech spending on a tight leash, ra...

Hospital leaders have become increasingly cautious about their spending and the ...

Respiratory viruses, thrown out of whack by Covid, appe...

As we head into the fourth Northern Hemisphere winter of the Age of Covid, respi...

Takeda wins EU approval for paediatric use of Takhzyro ...

The European Commission has approved the label expansion of Takeda’s Takhzyro (...